

Investor Newsletter

Issue **09** 2018



Firehawk® Clinical Data from the Target AC European Clinical Trial Has Been Accepted for Publication in the Prestigious Medical Journal **the Lancet**

On September 4, MicroPort Scientific Corporation ("MicroPort®") announced that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") which conducted a multi-center, randomized controlled trial called TARGET AC has been published online in The Lancet, a world leading medical journal currently ranked second out of 154 journals in the Medicine, General & Internal subject category.

"This is a landmark achievement by MicroPort® given that this is the first time that clinical data from a China manufactured drug eluting stent has been published in such a prestigious medical journal such as The Lancet," said Dr. Zhaohua Chang, Founder Chairman and CEO of MicroPort®. "With the Firehawk® clinical results having been validated in such a rigorous peer-reviewed publication, clinicians and patients should have every confidence in the safety and efficacy of Firehawk® to treat patients with coronary artery disease. We strongly believe and expect that the Firehawk® stent will be used to save millions of patients globally in the years to come. As a company, MicroPort® will continue to be at the forefront of developing and providing revolutionary medical technology solutions to meet the unending demand for health and longevity in extending patient lives."

THE LANCET

Log in Register Subscribe Claim

ARTICLES | ONLINE FIRST

Purchase Subscribe Save Share Reprints Request

Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial

 MicroPort

MicroPort® Spine Trauma's Full Series Instruments Granted Registration Approval in Brazil

Recently, the fracture instruments of Reindeer® Locking Compression Plate System and the instruments of Takin® Spinal Posterior Fixation System, both of which were independently developed by MicroPort Spine Trauma (Suzhou) Medical Technology Co., Ltd. ("MicroPort® Spine Trauma"), successfully received the approval for registration from Agencia Nacional Vigilancia de Sanitaria (ANVISA) of Brazil. It was also the first time that the products of MicroPort® Spine Trauma have been granted the registration approvals in Latin America.

With the largest market capacity in Latin America, Brazil is widely known for its high standard, rigorous requirements and long review period when granting access to the country's medical device market. It is expected that the approvals granted to the instruments of two major product lines of MicroPort® Spine Trauma will lay a solid groundwork for the future entry of the company's spine and trauma implant products into the Brazilian market. In future, MicroPort® Spine Trauma will continue to follow the management credo of MicroPort®, which is "Eyes for Greatness, Hands on Details", so as to innovate relentlessly to commercialize the best, yet affordable, therapeutic solutions to save and reshape patients' lives, or to improve their quality of life.






MicroPort® Firehawk® Appears at the High-level Meeting on China-Africa Health Cooperation

Recently, the High-level Meeting on China-Africa Health Cooperation, which was focused on "Intensifying China-Africa Health Cooperation, Jointly building a Silk Road of Health" and organized by National Health Commission of China, took place together with the 3rd Beijing Forum for Global Health and the 27th China International Medical Equipment Exhibition & Scientific Conference (China-Hospeq 2018) at the China National Convention Center in Beijing, China. The meeting featured in-depth discussions on the topics such as the building of disease control in Africa and China-Africa public health cooperation, the training of medical specialists, and innovation in China-Africa health cooperation models, so as to promote the matching of the policies of China and African countries.

On August 18 afternoon, Lei Sun, head of Center for Medical Device Evaluation of China State Drug Administration, and others visited the MicroPort® booth during the concurrent 27th China International Medical Equipment Exhibition & Scientific Conference (China-Hospeq 2018). Sun paid special attention to the product features and clinical proofs of the world's third generation coronary drug-eluting stent of Firehawk® system, as well as the development, current business and diversified product lines of MicroPort® in details. Thus far, a total of 14 products of MicroPort® or its related companies have been granted entry into the special review and approval procedure for innovative medical devices ("the Green Path"). Mr. Sun said that it was not only a recognition of the independent innovation of MicroPort®, but would also expedite the marketing progress of the products and benefit more patients.

MicroPort® Takes Firehawk® to Encore Seoul 2018 in Korea

From September 12 to 14, the 12th Annual Symposium of the Endovascular & Coronary Revascularization in Seoul (Encore Seoul 2018) took place in Seoul, Korea. More than 3,000 cardiologists from 18 countries were invited to attend the event, conducting comprehensive exchanges and discussions on the latest progress of the advanced therapies and clinical researches in the field of cardiology. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was present throughout the symposium and held an exclusive Firehawk® satellite conference, which showcased the latest clinical data and scientific results of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").



On September 14, the Firehawk® satellite conference happened as scheduled with every seat occupied and Professor Yang-Soo Jang, another director of Encore Seoul 2018 as guest moderator. During the event, Professor Niels van Royen spoke about the Firehawk® TARGET AC clinical study results and the OCT and QCA sub-study results. The participating prominent cardiologists in Korea, including Professor Jung Hwan Kim, Professor Ki Seok Kim and Professor Jae Woong Cho had a heated scientific discussion with Professor Niels van Royen.


As one of the most important markets in Asia-Pacific, the medical device market in Korea is very promising. Firehawk® entered the Korean market in 2017, with its first local implantation completed in March 2018. With more high-quality clinical data expected to be published and the progress of the Firehawk® clinical study in Korea, MicroPort® will continuously further explore the local market, so as to provide the patients with more comprehensive and best, yet affordable, medical solutions.

MicroPort® Appears at China Medical Devices Design & Startups Competition & Global Device Week (2018)

From September 6 to 9, China Medical Devices Design & Startups Competition & Global Device Week (2018) took place in Suzhou, China, as did Medical Fair China (MFC 2018) and China Medical Innovation Forum (CMIF 2018). MicroPort® and its subsidiary of Shanghai MicroPort Endovascular MedTech Co., Ltd. ("MicroPort® Endovascular") appeared at the events, presenting the achievements in the areas of platform building and innovation, technological innovation and management innovation.


During the opening ceremony, Professor Ge said that a high degree of emphasis has been placed on innovation from the top-level design to the medical device industry, as innovation is continually driving the development and progress of the cardiovascular discipline and helping cardiologists overcome hurdles one after another. During the speech, Professor Ge especially mentioned the innovative results achieved by MicroPort® in the field of coronary stent. He said that the MicroPort® stent has progressed from Firebird®, Firebird2® to Firehawk®, and pulled off a leap from the innovation of copy and improvement to the disruptive innovation. Recently, clinical data of Firehawk® TARGET AC study in Europe was published on the website of the world leading medical journal The Lancet, which is the first time that clinical data from a China manufactured drug eluting stent has been published in The Lancet since its first publication nearly 200 years ago.

At the event, MicroPort® Endovascular also presented the five products that had successively entered the Green Path, which are Castor® Branched Aortic Stent-Graft System ("Castor®"), Reewarm® PTX Drug Coated Balloon Dilation Catheter, Minos™ Ultra Low-Profile AAA Stent-Graft System, Talos™ Thoracic Stent Graft System and FONTUS™ Single-branched Stent Graft System in Surgical Operation. Of the five, Castor® was approved for registration and launched in June 2017. Thus far, a total of 14 products of MicroPort® or its related companies have been granted entry into the Green Path, which not only marks an endorsement of the independent innovation, but will also expedite the marketing progress of various kinds of high-tech medical devices and benefit more patients.



MicroPort® Brings Innovative Products to TCT 2018

From September 21 to September 25, the 30th Transcatheter Cardiovascular Therapeutics ("TCT") took place in San Diego, California, the US, gathering more than 10,000 cardiovascular interventionalists from over 100 countries and regions across the world. The event, including Presentation Theater Programs, Expert Case Reviews, and Hot Topic Sessions, served as a scientific banquet for the participants. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") brought to TCT its innovative products in the fields of interventional cardiology, structural heart and cardiac rhythm management, and attracted great attention from a wide range of visitors at TCT 2018.



On September 22 local time, Professor Andreas Baumbach from Queen Mary University of London and Professor Alexandra Lansky from Yale University School of Medicine, who were co-principal investigators in the TARGET AC clinical study of Firehawk® conducted in Europe, took part in the "Hi Tea with Investigators from TARGET AC Trial" session at the MicroPort® booth. The TARGET AC clinical outcomes were published on the website of the world leading medical journal The Lancet on September 3 UK time. This is the first time that clinical data from a China manufactured drug eluting stent has been published in The Lancet since its first publication nearly 200 years ago

On September 22 local time, Dr. Lei Song from Fuwai Hospital of Chinese Academy of Medical Sciences released the two-year clinical and angiographic follow-up results of FUTURE-I Study of Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®"). At 2 years, all 45 patients completed clinical follow-up and target lesion failure rate was 0% with no scaffold thrombosis and the occurrence of patient-oriented composite endpoint ("PoCE", including all-cause mortality, all myocardial infarction and any revascularization) was 2.2%. There was no report of death, target vessel myocardial infarction and scaffold thrombosis. Imaging follow-up in Cohort 1 at 2 years showed that in-segment lumen loss was 0.28 ± 0.28 mm, mean restenosis rate was 3.8%, strut endothelial coverage rate was 99.7%. OCT results at 2 years showed obvious degradation of scaffolds compared with former results. The 2-year results of the FUTURE-I Study confirmed the safety and efficacy of Firesorb® in the treatment of de novo coronary artery lesions. The experts in attendance discussed the results with Dr. Song and endorsed the 2-year clinical and angiographic outcomes of FUTURE-I.

MicroPort® Orthopedics Holds First University of Hong Kong - Shenzhen Hospital Total Knee Arthroplasty Technique (TKA) Advancement Course

The first Total Knee Arthroplasty Technique Advancement Course, which was co-organized by MicroPort® Orthopedics and University of Hong Kong - Shenzhen Hospital, took place on August 29. A total of 12 orthopedic surgeons from the Chinese provinces of Jiangsu, Sichuan, Shandong, Liaoning and Chongqing took part in the 2-day course on Medial-Pivot Knee TKA technique at University of Hong Kong - Shenzhen Hospital.

Thus far, the Total Knee Arthroplasty Technique Advancement Course co-organized by MicroPort® Orthopedics and Queen Mary Hospital has been successfully held for six times, with more and more orthopedic surgeons benefitting from the course. In future, MicroPort® Orthopedics will continually promote the scientific exchanges and help even more orthopedic surgeons understand and employ Medial-Pivot knee products in various forms including the Total Knee Arthroplasty Technique Advancement Course, so as to benefit the patients.



Suzhou MicroPort® Orthocare Holds 1st New Rehabilitation Technique Symposium

On September 9, Suzhou MicroPort® Orthocare, a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), held the first New Rehabilitation Technique Symposium. The symposium gathered more than 30 orthopedic or rehabilitation medicine professionals from across China, so as to lift the level of the domestic orthopedic and rehabilitation techniques and further drive the development of China's orthopedic and rehabilitation segments through the extensive and in-depth exchanges and discussions on the world's most advanced techniques in the orthopedic and rehabilitation areas.



With the symposium focused on Exchanges of New Orthopedic and Rehabilitation Techniques, the healthcare professionals in attendance discussed, experienced and gave feedbacks on the orthopedic and rehabilitation products and techniques, such as the wearable rehabilitation assessment system, the smart shoulder rehabilitation system and static & dynamic progressive range of motion splinting. They gave lots of valuable suggestions from the perspectives of the clinical demand, efficacy, prospect of application, patient experience and cost.

Suzhou MicroPort® Orthocare is rehabilitation and patient care focused subsidiary of MicroPort®. Following the management credo of "Eyes for Greatness, Hands on Details", the MicroPort® employees always hold the belief that they should serve the patients and the doctors who also serve the patients eventually. The MicroPort® employees will meet the unending demand for health and longevity in extending patient lives.

Experts from **Pakistan Society of Interventional Cardiology** Visits MicroPort®

On September 6, Professor Bashir Hanif, President of Pakistan Society of Interventional Cardiology, and Professor Amber Malik, General Secretary of the society, visited MicroPort®. The visit took place after the Pakistani experts attended a signing ceremony for the Sino-Pakistan “Belt and Road Interventional Cardiology Training Program”, which was co-hosted by Chinese Medical Doctor Association and China Cardiovascular Association during the 20th Scientific Annual Congress of Chinese Society of Cardiology & the 12th Qianjiang International Cardiovascular Conference.

Professor Hanif and Professor Malik also had positive exchanges and interactions with the MicroPort® employees. Professor Hanif said that the rich product lines and strong R&D capability of MicroPort® had left a deep impression on him, while the extremely fine manufacturing process and rigorous quality assurance system at the production facilities had also boosted his confidence in the high-end medical devices of MicroPort® and even China. He added that the cardiovascular diseases were the top fatal diseases in Pakistan, but lots of local patients suffering from the diseases lacked timely treatment with efficacy so far due to the shortages of catheter labs, various kinds of interventional devices and equipment, and the clinicians who had received cardiovascular interventional education and training in a systematic manner in Pakistan. He hoped for further cooperation with MicroPort® to introduce more high-end medical devices and services into Pakistan, so as to benefit more local patients.



In September 2016, Firehawk® acquired the registration approval from Drug Regulatory Authority of Pakistan (DRAP) and officially entered the Pakistan market. As of end of 2017, approximately 4.5 million coronary stents manufactured by MicroPort®, including the Firehawk® stent, have been implanted in about 3.5 million patients worldwide. Firehawk® has now been approved for use and marketed in 36 countries and territories globally.

Investor Newsletter

Issue **09** 2018



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com